200 related articles for article (PubMed ID: 34552593)
21. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
22. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA.
Yamanaka R; Yajima N; Tsuchiya N; Honma J; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG
J Neurosurg; 2002 Nov; 97(5):1184-90. PubMed ID: 12450042
[TBL] [Abstract][Full Text] [Related]
23. CXCL16/CXCR6 Axis Drives Microglia/Macrophages Phenotype in Physiological Conditions and Plays a Crucial Role in Glioma.
Lepore F; D'Alessandro G; Antonangeli F; Santoro A; Esposito V; Limatola C; Trettel F
Front Immunol; 2018; 9():2750. PubMed ID: 30542347
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.
Baker GJ; Chockley P; Yadav VN; Doherty R; Ritt M; Sivaramakrishnan S; Castro MG; Lowenstein PR
Cancer Res; 2014 Sep; 74(18):5079-90. PubMed ID: 25038230
[TBL] [Abstract][Full Text] [Related]
25. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
26. Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression.
De Boeck A; Ahn BY; D'Mello C; Lun X; Menon SV; Alshehri MM; Szulzewsky F; Shen Y; Khan L; Dang NH; Reichardt E; Goring KA; King J; Grisdale CJ; Grinshtein N; Hambardzumyan D; Reilly KM; Blough MD; Cairncross JG; Yong VW; Marra MA; Jones SJM; Kaplan DR; McCoy KD; Holland EC; Bose P; Chan JA; Robbins SM; Senger DL
Nat Commun; 2020 Oct; 11(1):4997. PubMed ID: 33020472
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of Aquaporin-1 mediates a microglial phenotype switch affecting glioma growth.
Hu F; Huang Y; Semtner M; Zhao K; Tan Z; Dzaye O; Kettenmann H; Shu K; Lei T
Exp Cell Res; 2020 Nov; 396(2):112323. PubMed ID: 33058832
[TBL] [Abstract][Full Text] [Related]
28. Cytokine therapy.
Ohno M; Natsume A; Wakabayashi T
Adv Exp Med Biol; 2012; 746():86-94. PubMed ID: 22639161
[TBL] [Abstract][Full Text] [Related]
29. Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma.
Matsuda M; Nimura K; Shimbo T; Hamasaki T; Yamamoto T; Matsumura A; Kaneda Y
J Neurooncol; 2011 May; 103(1):19-31. PubMed ID: 20730616
[TBL] [Abstract][Full Text] [Related]
30. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
31. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
32. Exposure to an enriched environment promotes the terminal maturation and proliferation of natural killer cells in mice.
Meng Z; Liu T; Song Y; Wang Q; Xu D; Jiang J; Li M; Qiao J; Luo X; Gu J; Tu H; Gan Y
Brain Behav Immun; 2019 Mar; 77():150-160. PubMed ID: 30590110
[TBL] [Abstract][Full Text] [Related]
33. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
34. P2Y14 receptor activation decreases interleukin-6 production and glioma GL261 cell proliferation in microglial transwell cultures.
Curet MA; Watters JJ
J Neurooncol; 2018 Mar; 137(1):23-31. PubMed ID: 29189936
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18-stimulated macrophages mediated by interferon-gamma-regulated nitric oxide.
Kito T; Kuroda E; Yokota A; Yamashita U
J Neurosurg; 2003 Feb; 98(2):385-92. PubMed ID: 12593627
[TBL] [Abstract][Full Text] [Related]
36. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
[TBL] [Abstract][Full Text] [Related]
37. Pro-inflammatory modification of cancer cells microsurroundings increases the survival rates for rats with low differentiated malignant glioma of brain.
Zaitsev S; Sharma HS; Sharma A; Manzhulo I; Polevshchikov A; Kudriavtsev I; Khotimchenko Y; Pak O; Bryukhovetskiy A; Bryukhovetskiy I
Int Rev Neurobiol; 2020; 151():253-279. PubMed ID: 32448611
[TBL] [Abstract][Full Text] [Related]
38. CD30 ligand deficiency accelerates glioma progression by promoting the formation of tumor immune microenvironment.
Duan J; Gao Y; Zhang X; Wang X; Wang B; Meng X; Yoshikai Y; Wang Y; Sun X
Int Immunopharmacol; 2019 Jun; 71():350-360. PubMed ID: 30952099
[TBL] [Abstract][Full Text] [Related]
39. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.
Nagashima S; Mailliard R; Kashii Y; Reichert TE; Herberman RB; Robbins P; Whiteside TL
Blood; 1998 May; 91(10):3850-61. PubMed ID: 9573023
[TBL] [Abstract][Full Text] [Related]
40. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma.
Chen B; Timiryasova TM; Haghighat P; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
J Immunother; 2001; 24(1):46-57. PubMed ID: 11211148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
